The US Food and Drug Administration (FDA) recently approved CooperVision’s MiSight, a contact lens indicated for the slow progression of myopia in children 8 to 12 years old.

This is the first FDA-approved contact lens designed for slowing myopic progression.

Myopia is nearsightedness, where a person is unable to clearly see objects that are far away. In many instances, myopia develops during childhood and continues to progress. Myopia is the most common type of visual impairment worldwide and its prevalence is on the rise. It can be corrected with glasses, contact lenses, or laser eye surgery.

Severe myopia in children increases the risk of developing other eye diseases in adulthood, such as retinal detachment and cataracts.

MiSight is a single-use daily soft contact lens that corrects visibility and also prevents the progression of myopia. The lens, like other soft contact lenses, is easy to use.

A three-year randomised clinical trial, which was conducted in four countries with an ethnically diverse sample, showed the lens was successful in slowing juvenile-onset myopia.

Additionally, CooperVision says the lens achieved full-time wear among participants and that children have responded positively to the experience of using the lenses.

CooperVision Inc is a subsidiary of Cooper Companies Inc.

CooperVision manufactures a wide array of monthly, two-week and daily disposable contact lenses. Its products are available in over 100 different countries.

For more insight and data, visit the GlobalData Report Store.